Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Healthy Alaskan.
Press releases published on May 7, 2025
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
GlobeNewswire
·
May 7, 2025
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter …
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
GlobeNewswire
·
May 7, 2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
GlobeNewswire
·
May 7, 2025
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire
·
May 7, 2025
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company’s headquarters, …
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 …
Best Probiotic For Women: Top Strains for Gut Health, Vaginal health & Constipation - Women Over 40,50,60 - Bioma
GlobeNewswire
·
May 7, 2025
Birštonas, May 07, 2025 (GLOBE NEWSWIRE) -- In this health-conscious era, choosing a good probiotic for women is no longer a supplement option—it's a lifestyle choice for women's health, digestion, and well-being; with so many probiotics on the market, …
The Best Place to Buy SARMs Online and OTC: Top SARM Brand & Company for Muscle Growth & Fat Loss - Safe Legal SARMS for Sale - CrazyBulk
GlobeNewswire
·
May 7, 2025
New York City, May 07, 2025 (GLOBE NEWSWIRE) -- The best place to buy SARMs is presented by CrazyBulk SARMs are the hottest trend in bodybuilding right now. Bodybuilders, weightlifters, and athletes everywhere are buying SARMs (Selective Androgen Receptor …
Best Legal Steroids for Muscle Growth & Testosterone Booster – Top Legal Supplements For Bulking, Cutting & Strength 2025 – By Wolfson Brands
GlobeNewswire
·
May 7, 2025
Glassgow, May 07, 2025 (GLOBE NEWSWIRE) -- Best Legal Steroids For Fastest Muscle Growth While the options in workout supplements are endless, here is a list of the five best options based on efficiency, results, price, and customer reviews. Read the basic …
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
GlobeNewswire
·
May 7, 2025
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
GlobeNewswire
·
May 7, 2025
VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to …
Yaqrit 的 HE 候选药物进入 3 期试验阶段并在 EASL 上展示了相关支持数据
GlobeNewswire
·
May 7, 2025
经 FDA 批准用于肝性脑病 3 期试验的一种改进型疾病分期工具，适用于静脉注射氨清除剂（YAQ006）。 口服氨清除剂（YAQ007）用于预防 HE 复发的剂量反应数据 氨清除剂作用机制的体内验证凸显与 TLR-4 拮抗剂（YAQ005）的潜在协同作用 伦敦, May 08, 2025 (GLOBE NEWSWIRE) -- Yaqrit 是一家聚焦临床后期阶段的公司，致力于开发治疗晚期肝病的救命疗法。本周，在 5 月 7 日至 10 日于阿姆斯特丹举行的欧洲肝脏研究协会（EASL …
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight
GlobeNewswire
·
May 7, 2025
New York, USA, May 07, 2025 (GLOBE NEWSWIRE) -- Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global …
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
GlobeNewswire
·
May 7, 2025
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in …
Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
GlobeNewswire
·
May 7, 2025
-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) -- BTK inhibition through the SH2 domain results in greater selectivity as compared to BTK tyrosine kinase …
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
GlobeNewswire
·
May 7, 2025
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated chikungunya vaccine …
Valneva fait un point suite à l'annonce de l'agence européenne des médicaments sur l'utilisation d'IXCHIQ® chez les personnes âgées
GlobeNewswire
·
May 7, 2025
Saint Herblain (France), le 07 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) a entamé une revue du vaccin vivant atténué contre le …